Effect of variability in anemia management on hemoglobin outcomes in ESRD

American Journal of Kidney Diseases

Volumn 41, Issue 1, 2003, Pages 111-124

  Lacson Jr , Eduardo ^a   Ofsthun, Norma ^a   Lazarus, J Michael ^a  

^a FRESENIUS MEDICAL CARE NORTH AMERICA   (United States)

Author keywords

Anemia; Clinical performance measure (CPM); End stage renal disease (ESRD); Erythropoietin (EPO); Health policy; Hematocrit (Hct); Hemoglobin (Hgb); Medicare; Quality of health care; Treatment algorithm

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; IRON;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HEMOGLOBIN DETERMINATION; HUMAN; IRON THERAPY; KIDNEY FAILURE; MALE; TREATMENT OUTCOME;

EID: 0037228098     PISSN: 02726386     EISSN: None     Source Type: Journal    
DOI: 10.1053/ajkd.2003.50030     Document Type: Article

References (63)

1. Eschbach JW, Kelly MR, Haley NR, Abels RI, Adamson JW: Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 321:158-163, 1989
2. The Canadian Erythropoietin Study Group: Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving hemodialysis. BMJ 300:573-578, 1990
3. McMahon LP, Dawborn JK: Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following the use of recombinant human erythropoietin. Am J Nephrol 12:162-169, 1992
4. Levin NW: Quality of life and hematocrit level. Am J Kidney Dis 1:S16-S20, 1992 (suppl 1)
5. Beusterien KM, Nissenson AR, Port FK, Kelly M, Steinwald B, Ware JE Jr: The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients. J Am Soc Nephrol 7:763-773, 1996
6. Moreno F, Sanz-Guajardo D, Lopez-Gomez JM, Jofre R, Valderrabano F: Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients. Spanish Cooperative Renal Patients Quality of Life Study Group of the Spanish Society of Nephrology. J Am Soc Nephrol 11:335-342, 2000
7. Mayer G, Thum J, Cada EM, Stummvoll HK, Graf H: Working capacity is increased following recombinant human erythropoietin treatment. Kidney Int 34:525-528, 1988
8. Macdougal IC, Lewis NP, Saunders MJ, et al: Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 335:489-493, 1990
9. Lundin AP, Akerman MJ, Chesler RM, et al: Exercise in hemodialysis patients after treatment with recombinant human erythropoietin. Nephron 58:315-319, 1991
10. Painter P, Moore GE: The impact of recombinant human erythropoietin on exercise capacity in hemodialysis patients. Adv Ren Replace Ther 1:55-65, 1994
11. Grimm G, Stockenhuber F, Schneeweiss B, Madl C, Zeitlhofer J, Schneider B: Improvement of brain function in hemodialysis patients treated with erythropoietin. Kidney Int 38:480-486, 1990
12. Marsh JT, Brown WS, Wolcott D, et al: rHuEPO treatment improves brain and cognitive function of anemic dialysis patients. Kidney Int 39:155-163, 1991
13. Temple RM, Deary IJ, Winney RJ: Recombinant erythropoietin improves cognitive function in patients maintained on ambulatory peritoneal dialysis. Nephrol Dial Transplant 10:1733-1738, 1995
14. Metry G, Wikstrom B, Valind S, et al: Effect of normalization of hematocrit on brain circulation and metabolism in hemodialysis patients. J Am Soc Nephrol 10:854-863, 1999
15. Schaefer RM, Kokot F, Wernze H, Geiger H, Heidland A: Improved sexual function in hemodialysis patients on recombinant erythropoietin: A possible role for prolactin. Clin Nephrol 31:1-5, 1989
16. Bommer J, Kugel M, Schwobel B, Ritz E, Barth HP, Seelig R: Improved sexual function during recombinant human erythropoietin therapy. Nephrol Dial Transplant 5:204-207, 1990
17. Wu SC, Lin SL, Jeng FR: Influence of erythropoietin treatment on gonadotropic hormone levels and sexual function in male uremic patients. Scand J Urol Nephrol 35:136-140, 2001
18. Massimetti C, Pontillo D, Feriozzi S, Costantini S, Capezzuto A, Ancarani E: Impact of recombinant human erythropoietin treatment on left ventricular hypertrophy and cardiac function in dialysis patients. Blood Purif 16:317-324, 1998
19. Jeren-Struji'c B, Raos V, Jeren T, Horvatin-Godler S: Morphologic and functional changes of left ventricle in dialyzed patients after treatment with recombinant human erythropoietin (r-HuEPO). Angiology 51:131-139, 2000
20. Eckardt KU: The CREATE trial - Building the evidence. Nephrol Dial Transplant 16:S16-S18, 2001 (suppl 2)
21. National Kidney Foundation: DOQI clinical practice guidelines for the treatment of anemia of chronic renal failure. Am J Kidney Dis 30:S192-S240, 1997 (suppl 3)
22. National Kidney Foundation: K/DOQI clinical practice guidelines for anemia of chronic kidney disease, 2000. Am J Kidney Dis 37:S182-S238, 2001 (suppl 1)
23. Barrett BJ, Fenton SS, Ferguson B, et al: Clinical practice guidelines for the management of anemia coexistent with chronic renal failure. Canadian Society of Nephrology. J Am Soc Nephrol 10:S292-S296, 1999 (suppl 13)
24. Working Party for European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure: European best practice guidelines for the management of anaemia in patients with chronic failure. Nephrol Dial Transplant 14:S1-S50, 1999 (suppl 5)
25. McMahon LP, McKenna MJ, Sangkabutra T, et al: Physical performance and associated electrolyte changes after haemoglobin normalization: A comparative study in haemodialysis patients. Nephrol Dial Transplant 14:1182-1187, 1999
26. Collins AJ, Li S, St Peter W, et al: Death, hospitalization, and economic associations among incident hemodialysis patients with hematocrit values of 36 to 39%. J Am Soc Nephrol 12:2465-2473, 2001
27. Xia H, Ebben J, Ma JZ, Collins AJ: Hematocrit levels and hospitalization risks in hemodialysis patients. J Am Soc Nephrol 10:1309-1316, 1999
28. Collins AJ, Ma JZ, Xia A, Ebben J: Trends in anemia treatment with erythropoietin usage and patient outcomes. Am J Kidney Dis 32:S133-S141, 1998 (suppl 4)
29. Ma JZ, Ebben J, Xia H, Collins AJ: Hematocrit level and associated mortality in hemodialysis patients. J Am Soc Nephrol 10:610-619, 1999
30. Collins AJ, Li S, Ebben J, Ma JZ, Manning W. Hematocrit levels and associated Medicare expenditures. Am J Kidney Dis 36:282-293, 2000
31. Besarab A, Bolton WK, Browne JK, et al: The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339:584-590, 1998
32. Macdougall IC, Ritz E: The Normal Haematocrit Trial in dialysis patients with cardiac disease: Are we any the less confused about target haemoglobin? Nephrol Dial Transplant 13:3030-3033, 1998
33. Nissenson AR: Optimal hematocrit in patients on dialysis. Am J Kidney Dis 32:S142-S146, 1998 (suppl 4)
34. Jacobs C: Normalization of haemoglobin: Why not? Nephrol Dial Transplant 14:S75-S79, 1999 (suppl 2)
35. Patterson P, Allon M: Prospective evaluation of an anemia treatment algorithm in hemodialysis. Am J Kidney Dis 32:635-641, 1998
36. Senger JM, Trenkle JA, St John WD: How to design an anemia management protocol. ANNA J 25:235-240, 1998
37. Watson C: Categorizing the response to epoetin alfa therapy. Case study of the anemic patient. ANNA J 26:629-632, 1999
38. Richardson D, Bartlett C, Will EJ: Intervention thresholds and ceilings can determine the haemoglobin outcome distribution in a haemodialysis population. Nephrol Dial Transplant 15:2007-2013, 2000
39. Health Care Financing Administration: 2001 Annual Report, End-Stage Renal Disease CMS Clinical Performance Measures Project. Baltimore, MD, Department of Health and Human Services, Health Care Financing Administration, Office of Clinical Standards and Quality, 2001, pp 8, 33-34
40. Dallman PR, Looker AC, Johnson CL, Carrol M: Influence of age on laboratory criteria for the diagnosis of iron deficiency anemia and iron deficiency in infants and children, in Hallberg L, Asp N-G (eds): Iron Nutrition in Health and Disease. London, UK, Libbey, 1996, pp 65-74
41. Godfrey K: Simple linear regression in medical research, in Bailar JC, Mosteller F (eds): Medical Uses of Statistics (ed 2). Boston, MA, New England Journal of Medicine Books, 1992, pp 201-232
42. US Renal Data System: Excerpts from the 2001 USRDS Annual Data Report. Am J Kidney Dis 38:S82 (Figs 4.4 and 4.5), 2001 (suppl 3)
43. Bayer Diagnostics: ADVIA 60, Product Specifications. Available at: www.bayerdiag.com. Accessed: November 11, 2002
44. Leonova JY, Kazanetz EG, Smetanina NS, Adekile AD, Efremov GD, Huisman TH: Variability in the fetal hemoglobin level of the normal adult. Am J Hematol 53:59-65, 1996
45. Jackson RT: Separate hemoglobin standards for blacks and whites: A critical review of the case for and unequal hemoglobin standards. Med Hypotheses 32:181-189, 1990
46. Maes M, De Meyer F: Relationships of climatic data to immune and hematologic variables in normal human. Neuroendocrinol Lett 21:127-136, 2000
47. Vasquez R, Villena M: Normal hematological values for healthy persons living at 4000 meters in Bolivia. High Alt Med Biol 2:361-367, 2001
48. Maes M, Scharpe S, Cooreman W, et al: Components of biological, including seasonal, variation in hematological measurements and plasma fibrinogen concentrations in normal humans. Experientia 51:141-149, 1995
49. Stam H, Hrachovina V, Stijnen T, Versprille A: Diffusing capacity dependent on lung volume and age in normal subjects. J Appl Physiol 76:2356-2363, 1994
50. Owen WF, Lowrie EG: C-reactive protein as an outcome predictor for maintenance hemodialysis patients. Kidney Int 54:627-636, 1998
51. Tonelli M, Blake PG, Muirhead N: Predictors of erythropoietin responsiveness in chronic hemodialysis patients. ASAIO J 47:82-85, 2001
52. Besarab A, Amin N, Ahsan M, et al: Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol 11:530-538, 2000
53. Kletzmayr J, Horl WH: Iron overload and cardiovascular complications in dialysis patients. Nephrol Dial Transplant 17:S25-S29, 2002 (suppl 2)
54. Chang CH, Chang CC, Chiang SS: Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 57:136-141, 2002
55. Salahudeen AK, Fleischmann E, Ahmed A, Bower JD: Anemia and iron target realization in 1998: Clinical management of anemia in 1,639 patients on hemodialysis. ASAIO J 47:511-515, 2001
56. Mittman N: Iron replacement in rHuEPO-treated dialysis patients: DOQI and beyond. Am J Kidney Dis 34:173-176, 1999
57. Mast AE, Blinder MA, Lu Q, Flax S, Dietzen DJ: Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood 99:1489-1491, 2002
58. Fishbane S, Shapiro W, Dutka P, Valenzuela OF, Faubert J: A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 60:2406-2411, 2001
59. Uehlinger DE, Gotch FA, Sheiner LB: A pharmacodynamic model of erythropoietin therapy for uremic anemia. Clin Pharmacol Ther 51:76-89, 1992
60. Medina A, Ellis C, Levitt MD: Use of alveolar carbon monoxide measurements to assess red blood cell survival in patients. Am J Hematol 46:91-94, 1994
61. Locatelli F, Olivares J, Walker R, et al: Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 60:741-747, 2001
62. Lynn RI, Elzein HA, Tharpe DL, et al: Anemia management: Hemoglobin variability considerations in evaluating patient outcomes and provider performance. J Am Soc Nephrol 11:284A, 2000 (abstr)
63. Roberts T, St. Peter WL, Keane WF, et al: How often do patients with a 3-month rolling average hematocrit 33-36% have monthly values ≥ 36% or ≥ 39%? J Am Soc Nephrol 11:295A, 2000 (abstr)